These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30884755)

  • 1. Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses.
    Bermejo M; Kuminek G; Al-Gousous J; Ruiz-Picazo A; Tsume Y; Garcia-Arieta A; González-Alvarez I; Hens B; Amidon GE; Rodriguez-Hornedo N; Amidon GL; Mudie D
    Pharmaceutics; 2019 Mar; 11(3):. PubMed ID: 30884755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evaluation of In Vitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media.
    Matsui K; Tsume Y; Amidon GE; Amidon GL
    J Pharm Sci; 2016 Sep; 105(9):2804-2814. PubMed ID: 27020985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical development of dexketoprofen.
    Mauleón D; Artigas R; García ML; Carganico G
    Drugs; 1996; 52 Suppl 5():24-45; discussion 45-6. PubMed ID: 8922555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.
    Hou HH; Jia W; Liu L; Cheeti S; Li J; Nauka E; Nagapudi K
    Pharm Res; 2018 Jan; 35(2):37. PubMed ID: 29380076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions.
    Bermejo M; Paixão P; Hens B; Tsume Y; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Löbenberg R; Lee A; Frances A; Amidon GE; Yu A; Salehi N; Talattof A; Benninghoff G; Sun D; Kuminek G; Cavanagh KL; Rodríguez-Hornedo N; Amidon GL
    Mol Pharm; 2018 Dec; 15(12):5454-5467. PubMed ID: 30372084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Dexketoprofen Trometamol in Healthy Volunteers After Single and Repeated Oral Doses.
    Barbanoj MJ; Gich I; Artigas R; Tost D; Moros C; Antonijoan RM; García ML; Mauleón D
    J Clin Pharmacol; 1998 Dec; 38(S1):33S-40S. PubMed ID: 29023869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Physiologically Based Pharmacokinetic Model for Studying the Biowaiver Risk of Biopharmaceutics Classification System Class I Drugs With Rapid Elimination: Dexketoprofen Trometamol Case Study.
    Zhang X; Ye X; Hu K; Li W; Li W; Xiao Q; Chen L; Yang J
    Front Pharmacol; 2022; 13():808456. PubMed ID: 35273497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs.
    Galia E; Nicolaides E; Hörter D; Löbenberg R; Reppas C; Dressman JB
    Pharm Res; 1998 May; 15(5):698-705. PubMed ID: 9619777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses.
    Barbanoj MJ; Gich I; Artigas R; Tost D; Moros C; Antonijoan RM; García ML; Mauleón D
    J Clin Pharmacol; 1998 Dec; 38(S1):33S-40S. PubMed ID: 9882080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
    Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
    Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents.
    Matsui K; Tsume Y; Amidon GE; Amidon GL
    Mol Pharm; 2015 Jul; 12(7):2418-28. PubMed ID: 25985298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the physiological variability of fasted gastric pH and tablet retention time on the variability of in vitro dissolution and simulated plasma profiles.
    Kovačič NN; Pišlar M; Ilić I; Mrhar A; Bogataj M
    Int J Pharm; 2014 Oct; 473(1-2):552-9. PubMed ID: 25064726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of dexketoprofen.
    Barbanoj MJ; Antonijoan RM; Gich I
    Clin Pharmacokinet; 2001; 40(4):245-62. PubMed ID: 11368291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.